Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Webinar series: Pneumococcus: an example of how bacteria can manipulate NETs to their advantage

Thursday, October 24, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article announces a webinar series focusing on the role of pneumococcus in manipulating neutrophil extracellular traps (NETs). This series aims to explore the therapeutic potential of targeting NETs in treating infections. Related articles discuss the prognostic value of cancer tests and the link between cytokines and sepsis.
Price reaction · baseline $14.19 (2024-10-23 close) · hit pre-market · 7 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
+2.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • The webinar series highlights innovative research on NETs.
  • It provides valuable insights into bacterial manipulation of immune responses.

Full Press Release Details

Click here for the next video in our series: NETs as a Therapeutic Target

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the webinar series?

The series focuses on how pneumococcus manipulates neutrophil extracellular traps (NETs).

What are NETs?

NETs are neutrophil extracellular traps that play a role in the immune response.

How can NETs be targeted therapeutically?

The webinar discusses the potential of targeting NETs to treat infections.

What related topics are covered in the article?

The article also mentions cancer tests and cytokine-induced changes in neutrophils.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare NETs pneumococcus therapeutic target cancer test
Last updated: Oct 24, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk